<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Strimvelis,  Common name - autologous CD34+ enriched cell fraction that
contains CD34+ cells transduced with retroviral vector that encodes for the
human ADA cDNA sequence.</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ZapfDingbats;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.NoNumHead2, li.NoNumHead2, div.NoNumHead2
	{mso-style-name:"NoNum\:Head2";
	mso-style-link:"NoNum\:Head2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.NoNumHead3, li.NoNumHead3, div.NoNumHead3
	{mso-style-name:"NoNum\:Head3";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.NoNumHead2Char
	{mso-style-name:"NoNum\:Head2 Char";
	mso-style-link:"NoNum\:Head2";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.tabletextNS, li.tabletextNS, div.tabletextNS
	{mso-style-name:"table\:textNS";
	mso-style-link:"table\:textNS Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.tabletextNSChar
	{mso-style-name:"table\:textNS Char";
	mso-style-link:"table\:textNS";
	font-family:"Arial Narrow",sans-serif;}
p.tableref, li.tableref, div.tableref
	{mso-style-name:"table\:ref";
	mso-style-link:"table\:ref Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.tablerefChar
	{mso-style-name:"table\:ref Char";
	mso-style-link:"table\:ref";
	font-family:"Arial Narrow",sans-serif;}
p.tablerefalpha, li.tablerefalpha, div.tablerefalpha
	{mso-style-name:"table\:ref \(alpha\)";
	mso-style-link:"table\:ref \(alpha\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.tablerefalphaChar
	{mso-style-name:"table\:ref \(alpha\) Char";
	mso-style-link:"table\:ref \(alpha\)";
	font-family:"Arial Narrow",sans-serif;}
p.Bullet, li.Bullet, div.Bullet
	{mso-style-name:Bullet;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.55pt;
	text-indent:-14.2pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.tabletext, li.tabletext, div.tabletext
	{mso-style-name:"table\:text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Narrow",sans-serif;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 56.7pt 56.7pt 56.7pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><img width=21 height=18 src="Strimvelis_files/image001.png"
alt="BT_1000x858px"><span lang=EN-GB>This medicinal product is subject to
additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section 4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Strimvelis 1-10 million cells/ml dispersion
for infusion. </span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=FR>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2.1     General description</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An autologous CD34<sup>+</sup> enriched
cell fraction that contains CD34<sup>+</sup> cells transduced with retroviral
vector that encodes for the human </span><span lang=EN-GB>adenosine deaminase (</span><span
lang=EN-GB>ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34<sup>+</sup>)
cells.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>2.2     Qualitative and quantitative
composition</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The finished product is composed of one or
more ethylene vinyl acetate (EVA) bags which contain an autologous CD34<sup>+</sup>
enriched cell fraction that contains CD34<sup>+</sup> cells transduced with
retroviral vector that encodes for the human ADA cDNA sequence.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:12.0pt'><span lang=EN-GB>The
quantitative information regarding CD34<sup>+</sup> cells/kg and total cells in
the product is presented in the labelling for each batch. The concentration is
1-10 million CD34<sup>+</sup> cells/ml.</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><u><span lang=EN-GB>Excipient with known effect</span></u></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB style='color:black'>This medicinal
product contains 0.15</span><span lang=EN-GB> mmol sodium per ml<span
style='color:black'> (see section 4.4).</span></span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3.       PHARMACEUTICAL </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>FORM</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dispersion for infusion.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>A
cloudy to clear, colourless to pink dispersion of cells. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL</span></b><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>
PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is indicated for the treatment <span
style='color:black'>of patients with severe</span> combined immunodeficiency
due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human
leukocyte antigen (HLA)-matched related stem cell donor is available (see
section 4.2 and section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2     Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis must be administered in a
specialist transplant centre, by a physician with previous experience in the treatment
and management of patients with ADA-SCID and in the use of autologous CD34<sup>+</sup>
<i>ex vivo</i> gene therapy products.  Strimvelis should only be administered
after consultation with the patient and/or family. </span><span lang=EN-GB
style='color:black'>Patients are expected to </span><span lang=EN-GB
style='color:black'>enrol in a post-treatment registry and will be followed-up
long term.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A CD34<sup>+</sup> stem cell back-up
containing at least 1 million CD34<sup>+</sup> cells per kg is required. This
should be harvested from the patient at least 3 weeks prior to treatment with<i>
</i></span><span lang=EN-GB>Strimvelis</span><span lang=EN-GB>. The stem cell
back-up is collected for use as rescue treatment should there be a failure
during product manufacture, transplant failure, or prolonged bone marrow
aplasia after treatment with<i> </i></span><span lang=EN-GB>Strimvelis</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The patient must be
able to donate </span><span lang=EN-GB style='color:black'>adequate CD34<sup>+</sup>
cells to deliver the minimum 4 million purified CD34<sup>+</sup>&nbsp;cells/kg,
</span><span lang=EN-GB style='color:black'>required for manufacture of Strimvelis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is intended for autologous use
only (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Before infusion, it must be confirmed that
the patient’s identity matches the essential unique patient information on the </span><span
lang=EN-GB>Strimvelis</span><span lang=EN-GB> infusion bag(s) and/or container
(see sections 4.4 and 6.6). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pre-treatment
conditioning</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>It is recommended that 0.5
mg/kg intravenous busulfan be administered every 6 hours on two consecutive
days starting three days before administration of Strimvelis. The total busulfan
dose is 4&nbsp;mg/kg, divided into 8 doses of 0.5&nbsp;mg/kg.</span><span
lang=EN-GB>  Busulfan plasma levels should be measured after the first dose of
each day by serial blood sampling using an appropriate method.  If busulfan AUC
exceeds 4000&nbsp;nanograms/ml*h (974&nbsp;µmol/L.minute), the dose should be appropriately
reduced based on the AUC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Premedication</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>It is recommended that
an intravenous antihistamine be administered</span><span lang=EN-GB>
15-30&nbsp;minutes before the<span style='color:black'> infusion</span> of <span
style='color:black'>Strimvelis</span>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The recommended dose</span><span
lang=EN-GB> range of <span style='color:black'>Strimvelis</span> is between 2
and 20 million CD34<sup>+</sup> cells/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the product contains
less than 2 million CD34<sup>+</sup> cells/kg, the treating physician should
make a decision whether to proceed with administration, based on an individual
benefit risk assessment.</span><span lang=EN-GB> </span><span lang=EN-GB
style='color:black'>Treatment failure was observed in a patient treated in the
clinical trials with &lt;2 millions CD34<sup>+</sup>cell/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis</span><span lang=EN-GB> should
be administered once only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis</span><span
lang=EN-GB> is not intended for use in patients &gt;65&nbsp;years of age, and
has not been studied in this age group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis<span
style='layout-grid-mode:line'> has not been studied in patients with renal
impairment. No dose adjustment is expected to be required.</span></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis<span
style='layout-grid-mode:line'> has not been studied in patients with hepatic
impairment. No dose adjustment is expected to be required.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The safety and
efficacy of Strimvelis in children less than six months of age or over 6&nbsp;years
1&nbsp;month has not been established (see section 4.4). No data are available.
</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration </span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis</span><span lang=EN-GB> is for
intravenous infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A transfusion
administration set with filter should be used.  Only filters intended for use
with transfusion sets should be used to prevent inadvertent removal of cells
from the product. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The infusion rate should not exceed
5&nbsp;ml/kg/h. The period of administration is approximately 20&nbsp;minutes
(see section 6.6).  </span><span lang=EN-GB>Following administration, a saline
filled 50&nbsp;ml syringe should be used to flush the bag through.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Precautions to be taken before
manipulating or administering the product</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains
genetically-modified cells. Local biosafety guidelines applicable for such
products should be followed (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is not tested for transmissible
infectious agents. Healthcare professionals handling Strimvelis should
therefore take appropriate precautions to avoid potential transmission of
infectious diseases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity to
the product or to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Current or previous history of leukaemia or
myelodysplasia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Positive test for human immunodeficiency
virus (HIV) or presence of any other transmissible infectious agent listed in
the current EU Cell and Tissue Directive</span><span lang=EN-GB> </span><span
lang=EN-GB>prior to bone marrow harvest.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>History of previous gene therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is intended solely for
autologous use and should never be administered to any patient other than the
original CD34<sup>+</sup> cell donor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>In some cases the patient may be unable to
receive Strimvelis because of manufacturing issues. <span style='color:black'>After
notification, the treating physician may need to modify the treatment program
of the patient accordingly (i.e. terminating the busulfan conditioning and/or
administration of the stem cell back up treatment if appropriate).</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Stage two quality
control results will only be available after the product has been infused.  If
clinically relevant quality issues, such as out of specification results, are
identified after Strimvelis has been infused, the treating physician will be
notified.  The physician should monitor and/or treat the patient as
appropriate.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis should be used with caution in patients
older than 6&nbsp;years and 1&nbsp;month and younger than 6 months as there are
no data from clinical trials in these age ranges.</span><span lang=EN-GB
style='color:#365F91'> </span><span lang=EN-GB>Older patients are typically
less able to donate high numbers of CD34<sup>+</sup> cells which may mean that
older patients cannot be treated.  Successful generation of T cells after Strimvelis
is also likely to be affected by residual thymic function which can become
impaired in older children.  Use of Strimvelis in patients older than those
previously studied should be carefully considered and reserved only for
occasions where all other reasonable treatment options have been exhausted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who have previously tested
positive for hepatitis C can be treated with Strimvelis, provided they demonstrate
absence of ongoing infection using a nucleic acid test with a limit of
quantification of </span><span lang=EN-GB style='font-family:Symbol'>£</span><span
lang=EN-GB>15 international units/ml. Negative test results are required on at
least 3 sequential occasions over a period of at least 4 weeks, after completion
of treatment for hepatitis C, with the final test conducted no more than 3 days
prior to cell harvest.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis should be used with caution in patients
with hypersensitivity to aminoglycosides or bovine serum albumin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No cases of leukaemia or myelodysplasia
have been reported following treatment with Strimvelis. However, vector
insertions into chromosomal regions previously associated with leukaemia in
comparable trials of gene therapy in Wiskott Aldrich Syndrome, X-SCID and
Chronic Granulomatous Disease have been documented. Retroviral insertion sites
(RIS) have been detected adjacent to or within CCND2 and LMO2 and there is a potential
risk of leukaemic transformation following treatment with Strimvelis. It is
recommended that patients be monitored long term with at least annual visits
for the first eleven years and then at 13 and 15 years post treatment with
Strimvelis, to include a complete blood count with differential, biochemistry
and thyroid stimulating hormone<i>. </i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The long term effects and durability of
response to Strimvelis on ADA-SCID are unknown (see section 5.1).  </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be closely monitored for
the occurrence of severe and opportunistic infections, immune reconstitution
parameters and the need for replacement intravenous immunoglobulin (IVIG); in
case of lack of response, it is recommended to introduce other ADA-SCID treatments
under the supervision of a physician.</span></p>

<p class=MsoNormal><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span lang=EN-GB>There have been cases where treatment with
Strimvelis<i> </i>has been unsuccessful. Some patients have had to resume
long-term enzyme replacement therapy and/or receive a stem cell transplant (see
section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non-immunological manifestations of
ADA-SCID may not respond to Strimvelis. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No immunogenicity testing has been
conducted with Strimvelis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients can develop autoimmunity. 67% (12
of 18) of Strimvelis treated patients had either autoimmune antibodies or other
manifestations (e.g. autoimmune thrombocytopenia, autoimmune aplastic anaemia,
autoimmune hepatitis and Guillain-Barré syndrome) (see section 4.8).</span></p>

<p class=MsoNormal><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span lang=EN-GB>Patients treated with Strimvelis should not
donate blood, organs, tissues and cells for transplantation, at any time in the
future. This information is provided in the Patient Alert Card. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>T&#8209;lymphocyte (CD3+) and NK (CD56+)
cell counts improved following treatment with Strimvelis.  Median values at 3
years post gene therapy were below the normal range. Continued follow-up is
recommended.  Cases of skin papillomas, abnormal serum protein electrophoresis
and one case each of lipofibroma, pulmonary mass and decreased T-cell V beta
repertoire were reported. No evidence of causality to the product has been
established. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse events related to the use of
central venous catheters (CVCs) have been reported (e.g., serious CVC
infections and thrombosis in the device). Patients should be closely monitored
for potential catheter-related events.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Sodium
content</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains <span style='color:black'>0.15</span>
mmol sodium per ml. To be taken into consideration by patients on a controlled
sodium diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.5     Interaction with other medicinal products and other forms of
interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No interaction studies have been performed.
Strimvelis is not expected to interact with the hepatic cytochrome P-450 family
of enzymes or drug transporters. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
childbearing potential</span></u></p>

<p class=MsoNormal><span lang=EN-GB>As Strimvelis will be administered
following busulfan conditioning, p<span style='color:black'>atients of
childbearing potential must use reliable barrier contraception during
administration of Strimvelis and for at least 6 months afterwards.</span></span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>No clinical data on exposed pregnancies are
available.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Reproductive and
developmental toxicity studies were not performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB style='font-size:11.0pt'>Strimvelis should not be used during
pregnancy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>It is unknown whether
Strimvelis is excreted in human milk.</span><span lang=EN-GB> The effect on
breast-fed infants of administration of Strimvelis to their mothers has not
been studied.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis should not be administered to
women who are breast-feeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There are no data on the effects of Strimvelis
on human fertility. Effects on male and female fertility have not been
evaluated in animal studies.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Strimvelis has no or
negligible long term influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.8     Undesirable
effects</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety of Strimvelis<i> </i>was
evaluated in 18 subjects, with a median duration of follow-up of 12 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>Given the small patient population and size
of the cohorts, adverse reactions in the table do not provide a complete
perspective on the nature and frequency of these events.  Serious adverse
reactions include autoimmunity (e.g. autoimmune haemolytic anaemia,</span><span
lang=EN-GB> </span><span lang=EN-GB>autoimmune aplastic anaemia, autoimmune
hepatitis, autoimmune thrombocytopenia and Guillain-Barré syndrome). The most
commonly reported adverse reaction was pyrexia.  </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid;text-autospace:none'><u><span lang=EN-GB>Tabulated list
of adverse reactions</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid;text-autospace:none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Adverse reactions are listed below by MedDRA body system organ class
and by frequency. The frequency categories used are:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Very common  <u>&gt;</u> 1/10</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Common          </span><span lang=EN-GB style='font-family:Symbol'>³</span><span
lang=EN-GB>1/100 to &lt;1/10</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=555
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>System organ class</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>Very common</span></b></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>Common</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Anaemia<sup>a</sup><br>
  Neutropenia<sup>a</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Autoimmune haemolytic anaemia, autoimmune aplastic
  anaemia, autoimmune thrombocytopenia</span></p>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Endocrine disorders</span></b></p>
  </td>
  <td width=164 valign=bottom style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Hypothyroidism</span></p>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Autoimmune thyroiditis</span></p>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:25.15pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Guillain-Barré
  syndrome</span></p>
  </td>
 </tr>
 <tr style='height:21.45pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.45pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.45pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Hypertension<sup>a</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.45pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='color:black'>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='height:39.25pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Asthma, rhinitis allergic</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='color:black'>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='height:28.95pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Hepatobiliary disorders</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Autoimmune hepatitis</span></p>
  </td>
 </tr>
 <tr style='height:39.25pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dermatitis
  atopic, eczema</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='color:black'>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='height:39.25pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>General disorders and administration site conditions</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pyrexia</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='color:black'>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='height:39.25pt'>
  <td width=221 valign=top style='width:165.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Investigations</span></b></p>
  </td>
  <td width=164 valign=top style='width:122.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hepatic
  enzyme increased<sup>a</sup></span><span lang=EN-GB style='color:black'>,
  antinuclear antibody (ANA) positive, smooth muscle antibody positive</span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Antineutrophil cytoplasmic antibody positive </span></p>
  </td>
 </tr>
</table>

<p class=tablerefalpha><sup><span lang=X-NONE style='font-size:11.0pt;
font-family:"Times New Roman",serif'>a</span></sup><span lang=X-NONE
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Adverse reactions
considered potentially related to busulfan conditioning</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Immune reconstitution</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>All the identified adverse reactions in the
table (apart from those potentially related to busulfan) are considered to be
related to immune reconstitution, due to their nature and timing.  These
autoimmune adverse reactions were reported for subjects post-gene therapy. The
majority were reported during the 3 month to 3 year follow-up period and
resolved, with the exception of hypothyroidism and positive ANA tests.  In
addition, the allergy related adverse reactions in the table were reported
mostly during the 3 month to 3 year follow-up period.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No data from clinical studies are available
regarding overdose of Strimvelis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Immunostimulants,
other immunostimulants , ATC code: <span style='background:lightgrey'>not yet
assigned</span></span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal><span lang=EN-GB>After infusion, CD34<sup>+</sup> cells
engraft in the bone marrow where they repopulate the haematopoetic system with
a proportion of cells that express pharmacologically active levels of the ADA
enzyme.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Following successful
engraftment in the patient, the effects of the product are expected to be
life-long.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The median percentages of genetically
modified cells in peripheral blood at one year and 3 years after treatment, for
the patients enrolled in the pivotal study, were 28% (range 6%-92%) and 30%
(range 8%-101%) of CD19+, and 73% (range 20%-100%) and 67% (range 39%-82%) of
CD3+ cells, respectively. The median percentages of genetically modified cells
in peripheral blood at year 8 for the patients enrolled in the long-term
follow-up were 97% (range 1%-101%) of CD19+, and 101% (range 1%-101%) of CD3+ cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The presence of
the transgene leads to increased expression of ADA. One&nbsp;year post
treatment, median ADA activity (mononuclear cells adenosine deaminase) in
peripheral blood lymphocytes was 181.2 (range 42.1-1678.2)&nbsp;nmol/h/mg
protein, compared to a baseline median (range) of 80.6
(30.5-92.3)&nbsp;nmol/h/mg protein.  ADA activity remained increased throughout
the duration of the 8 year follow up.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A total of 18 patients with ADA-SCID were
treated with Strimvelis<i> </i>as part of one open-label pivotal trial
(AD1115611; N=12), two early open-label pilot studies (AD1117054/AD1117056;
N=3), and a compassionate use program (AD1117064; N=3). Studies evaluated the
use of Strimvelis with a range of </span><span lang=EN-GB>0.9&nbsp;million –
18.2&nbsp;million CD34<sup>+</sup> cells/kg. </span><span lang=EN-GB>All patients
received busulfan conditioning prior to gene therapy, with most receiving a
total dose of 4 mg/kg intravenously over 2 consecutive days prior to CD34<sup>+</sup>
infusion. Four subjects had previously received an unsuccessful stem cell transplant
from a haploidentical donor and 15 of 18 subjects had previously received prior
enzyme replacement therapy with polyethylene&#8209;glycol&#8209;modified bovine
adenosine deaminase (PEG-ADA). Patients who previously received PEG-ADA had
this treatment withdrawn 10 to 22 days prior to Strimvelis therapy. </span><span
lang=EN-GB>The median age across the program was 1.7&nbsp;years (range 0.5 to
6.1) and 61% were males. Eighty three percent were white (56%
Caucasian/European heritage and 28% Arabic/North African heritage), 11% </span><span
lang=EN-GB>African American/African, and 6% Asian.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Patients treated within the pivotal study</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of Strimvelis<i> </i>was
evaluated in a 3-year open-label, prospective study in children who lacked a
sibling HLA matched stem cell donor and were either failing to respond
adequately to PEG-ADA, were intolerant or did not have access to it.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Results at 3 years for patients treated
within the pivotal study<b> </b>are presented in Table 1. Treatment with Strimvelis
resulted in a 100% survival rate at 3 years post therapy, a decrease in the
severe infection rate, an increase in T&#8209;lymphocytes (CD3+) and all
subjects having post-baseline venous <span style='color:#2E2E2E'>red blood cell
deoxyadenosine nucleotide</span> (RBC dAXP) levels below pathological <span
style='color:black'>levels (&gt;</span>100&nbsp;nmol/ml).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 1. Results at 3 years for the ITT
population in the pivotal study*</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="46%" valign=top style='width:46.56%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><b><span lang=EN-GB
  style='line-height:115%'>Endpoint</span></b></p>
  </td>
  <td width="24%" valign=top style='width:24.14%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><b><span lang=EN-GB
  style='line-height:115%'>Baseline/ Pre&#8209;Treatment<sup>a</sup></span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.32%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><b><span lang=EN-GB
  style='line-height:115%'>Year 3/ 3 Years Post&#8209;Treatment<sup>b</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign=top style='width:46.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>Survival </span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>n</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>%</span></p>
  </td>
  <td width="24%" valign=top style='width:24.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>Not applicable</span></p>
  </td>
  <td width="29%" valign=top style='width:29.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>12</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>100%</span></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign=top style='width:46.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>Severe infections </span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>n</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>Rate of severe infections per person-year of
  observation (95% confidence interval)</span></p>
  </td>
  <td width="24%" valign=top style='width:24.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>12</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>1.10 (0.74-1.58)</span></p>
  </td>
  <td width="29%" valign=top style='width:29.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>12</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'> 0.429 <sup>c</sup> (0.24-0.72)</span></p>
  <p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign=top style='width:46.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>T-lymphocyte (x10<sup>6</sup>/l) </span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>n</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>median (range)</span></p>
  </td>
  <td width="24%" valign=top style='width:24.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>11</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>88.0 (19-2718)</span></p>
  </td>
  <td width="29%" valign=top style='width:29.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>11</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>828.0 (309-2458)</span></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign=top style='width:46.56%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>% subjects with venous RBC dAXP &lt;100&nbsp;nmol/ml
  after Strimvelis<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>n</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>%</span></p>
  </td>
  <td width="24%" valign=top style='width:24.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>Not applicable</span><sup><span lang=EN-GB
  style='font-size:10.0pt;line-height:115%'>e</span></sup></p>
  </td>
  <td width="29%" valign=top style='width:29.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>11</span></p>
  <p class=MsoNormal style='line-height:115%'><span lang=EN-GB
  style='line-height:115%'>100%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>*</span></sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'> Including <span style='color:black'>data
from one patient collected post intervention with PEG-ADA (<u>&gt;</u>3 months
treatment) or hematopoietic stem cell transplantation</span></span></p>

<p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'> Based on the entire pre-treatment
period for severe infections (retrospectively collected), and the data
collected at the baseline visit for T&#8209;lymphocytes. Patient 10 had no
baseline value for T&#8209;lymphocytes.</span></p>

<p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>b </span></sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>Based on the 3 year post-treatment
period for survival and severe infections, and the data collected at the 3 year
visit for T&#8209;lymphocytes and dAXP. Patient 8 withdrew from the study
before 3 year visit, and thus had no data for T&#8209;lymphocytes and dAXP.</span></p>

<p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>c </span></sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%;color:black'>Severe infections are
those requiring or prolonging hospitalisation. The 3 month hospitalisation
period immediately post gene therapy was excluded from the calculation</span></p>

<p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>d </span></sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>dAXP=dAMP+dADP+dATP. dAXP results are
based on a responder analysis of the percentage of patients following gene
therapy who met the definition of adequate metabolic detoxification, therefore
baseline value is not applicable.</span></p>

<p class=MsoNormal style='line-height:115%'><sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>e </span></sup><span lang=EN-GB
style='font-size:10.0pt;line-height:115%'>At baseline 9 of 11 (82%) patients
had dAXP &lt;100&nbsp;nmol/ml. All these patients had previously taken PEG-ADA.
</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>T cell function:</span></i><span
lang=EN-GB> <span style='color:black'>In the patients treated in the pivotal
study, T cell proliferation was demonstrated in response to stimulation with
anti-CD3 antibodies (median 62629 cpm, range 4531 to 252173) and
phytohemaglutinin (median 140642 cpm, range 11119 to 505607) at 1 year post
gene therapy, and these responses were sustained through Year 3. </span></span><span
style='color:black'>Findings that TREC (T cell receptor excision circles) in
peripheral blood lymphocytes were increased above baseline </span><span
lang=EN-GB style='color:black'>(median 141, range 56 to 1542 copies/100ng DNA)</span><span
lang=EN-GB style='color:black'> </span><span style='color:black'>at Years 1 and
maintained to 3 post-treatment and that all subjects had evidence of polyclonal
V&#8209;beta chains at one or more time points following gene therapy provides
further supportive evidence of functional T cell development.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>B cell function:</span></i><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB>All 12 subjects treated
in the pivotal study were receiving IVIG therapy at the time of screening, and 7
subjects (58%) had discontinued IVIG use during 0-3 years follow-up after gene
therapy.</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-GB style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Long-term follow-up</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A 100% survival rate was observed for all 12
subjects treated within the pivotal study and also for the 18 subjects in the
integrated analysis, with a median follow up duration of approximately 12 years.
</span><span lang=EN-GB>Intervention-free survival in this pivotal population
(defined as survival without the requirement for long-term (</span><span
lang=EN-GB style='font-family:Symbol'>³</span><span lang=EN-GB>3 month)
re-introduction of PEG-ADA, or stem cell transplant) was 92% (11/12 subjects) (</span><span
lang=EN-GB>82% (14</span><span lang=EN-GB>/17 subjects) </span><span
lang=EN-GB>for integrated population)</span><span lang=EN-GB>. One subject
treated in a pilot study did not have PEG-ADA re-introduction data, and thus
was excluded from the intervention-free survival in the integrated population.</span><span
lang=EN-GB> Long-term PEG-ADA (exceeding 3 months of continuous duration) was
used by three subjects; two of these subjects subsequently received a
sibling-matched stem cell transplant and one subject<b><i> </i></b>remained on
chronic PEG-ADA treatment. </span><span lang=EN-GB>Another subject needed
transient PEG-ADA administration due to an autoimmune event (see section 4.4).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-GB style='line-height:
115%;color:black'>In those patients treated in the pivotal and long-term
follow-up (LTFU) study, the rate of severe infections declined throughout the
follow-up period (Table 2).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk27503149"><b><span
lang=EN-GB>Table 2 Cumulative rate of severe infections </span></b></a><b><span
lang=EN-GB>per person year of exposure (combined pivotal and LTFU ITT population)*</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=659
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=83 valign=top style='width:62.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=75 valign=top style='width:56.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pre
  treatment</span></p>
  </td>
  <td width=501 colspan=8 valign=top style='width:375.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Post
  treatment</span></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Time
  period </span></p>
  </td>
  <td width=75 valign=top style='width:56.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>n/a</span></p>
  </td>
  <td width=60 valign=top style='width:45.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3 mths - 1
  year</span></p>
  </td>
  <td width=72 valign=top style='width:53.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2 years</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3 years</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>4 years</span></p>
  </td>
  <td width=60 valign=top style='width:44.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5 years</span></p>
  </td>
  <td width=60 valign=top style='width:44.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>6 years</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to 7
  years</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Up to </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>8 years</span></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No. of
  subjects</span></p>
  </td>
  <td width=75 valign=top style='width:56.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>17</span></p>
  </td>
  <td width=60 valign=top style='width:45.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>17</span></p>
  </td>
  <td width=72 valign=top style='width:53.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>17</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>17</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>16</span></p>
  </td>
  <td width=60 valign=top style='width:44.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width=60 valign=top style='width:44.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>15</span></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No. of severe
  infections</span></p>
  </td>
  <td width=75 valign=top style='width:56.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>32</span></p>
  </td>
  <td width=60 valign=top style='width:45.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>11</span></p>
  </td>
  <td width=72 valign=top style='width:53.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>18</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>18</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>20</span></p>
  </td>
  <td width=60 valign=top style='width:44.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>20</span></p>
  </td>
  <td width=60 valign=top style='width:44.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>21</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>21</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>21</span></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rate of
  severe infections per person year</span></p>
  </td>
  <td width=75 valign=top style='width:56.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.86</span></p>
  </td>
  <td width=60 valign=top style='width:45.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.73</span></p>
  </td>
  <td width=72 valign=top style='width:53.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.56</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.35</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.30</span></p>
  </td>
  <td width=60 valign=top style='width:44.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.24</span></p>
  </td>
  <td width=60 valign=top style='width:44.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.22</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.19</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0.17</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:10.0pt'>* Excluding <span style='color:black'>data from one
patient from the Pilot 1 study who was not followed up until year 13 after gene
therapy.               n/a: not applicable.</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is an autologous cellular
therapy. The nature of Strimvelis is such that conventional studies on
pharmacokinetics, absorption, distribution, metabolism, and elimination are not
applicable.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Reproductive and
developmental studies have not been conducted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A 4&#8209;month
biodistribution study was performed in mice.  CD34<sup>+</sup> cells derived
from healthy human umbilical cord blood, transduced with the vector used for
the production of </span><span lang=EN-GB>Strimvelis<span style='color:black'>,
were administered intravenously to busulfan-conditioned mice. The majority of mice
showed reconstitution of the haematopoietic system by the end of the study. Low
levels of human cells and vector sequences were also detected in
non-haematopoietic organs consistent with the presence of blood containing
transduced human cells. There were no adverse effects on survival,
haematological parameters or histopathology of major organs, apart from body
weight loss and atrophy in the testes and ovaries consistent with
administration of busulfan.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Carcinogenicity studies have not been
conducted as no adequate animal model was available to evaluate the
tumourigenic potential of Strimvelis </span>due to the inability to achieve
long-term engraftment of transduced cells in mice.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the absence of compatibility studies,
this medicinal product must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>6 hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store at 15-30</span><span lang=EN-GB
style='font-family:Symbol'>°</span><span lang=EN-GB>C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.5     Nature
and contents of container </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>50&nbsp;ml ethylene vinyl acetate (EVA)
infusion bag</span><span lang=EN-GB>, with a luer spike interconnector closed
with a luer lock cap</span><span lang=EN-GB>,</span><span lang=EN-GB> </span><span
lang=EN-GB>packed in a re-usable outer container.</span></p>

<p class=MsoNormal><a name="OLE_LINK1"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal><b><span lang=EN-GB>6.6     Special precautions for disposal
and other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is transported directly to the
medical facility where the infusion will be administered. The infusion bag(s)
is/are placed inside a closed outer container. The bags must be kept in the
outer container until ready to use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is intended solely for
autologous use. The identity of the patient must be matched with the essential
unique patient information on the primary and/or outer container prior to
infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Gently agitate the
infusion bag to re-disperse any cellular aggregates, administer using a
transfusion administration set with filter to remove any remaining cellular
aggregates.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains
genetically-modified cells.  Local biosafety guidelines applicable should be
followed (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is not tested for transmissible
infectious agents. Healthcare professionals handling Strimvelis should
therefore take appropriate precautions to avoid potential transmission of
infectious diseases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Work surfaces and material which have
potentially been in contact with Strimvelis must be decontaminated with
appropriate disinfectant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local biosafety requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Orchard Therapeutics (Netherlands) BV</span></p>

<p class=MsoNormal><span lang=EN-GB>Prins Bernhardplein 200, </span></p>

<p class=MsoNormal><span lang=EN-GB>1097 JB Amsterdam, </span></p>

<p class=MsoNormal><span lang=EN-GB>the Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/16/1097/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 26 May 2016</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>MM/YYYY</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>A.        MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>B.        CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>C.        OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>D.        <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
product</span></span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.      MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturer of the biological active substance </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AGC Biologics
S.p.A.<br>
58 Via Olgettina<br>
20132<br>
Milan<br>
Italy</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AGC Biologics
S.p.A.<br>
58 Via Olgettina<br>
20132<br>
Milan<br>
Italy</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><a name="OLE_LINK2"><span lang=EN-GB>B.</span></a><span
lang=EN-GB>      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF
THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The requirements for submission of periodic safety update reports
for this medicinal product are set out in the list of Union reference dates
(EURD list) </span><span lang=EN-GB>provided for under Article 107c(7) of
Directive 2001/83</span><span lang=EN-GB>/EC</span><span lang=EN-GB> and </span><span
lang=EN-GB>any subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder shall submit the first periodic safety update report for
this product within 6&nbsp;months following authorisation.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=TitleB><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT  </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The MAH shall perform the required pharmacovigilance activities and
interventions detailed in the agreed RMP presented in Module 1.8.2 of the
Marketing Authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-10.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Prior to launch of Strimvelis in each Member State, the Marketing
Authorisation Holder (MAH) must agree about the content and format of the
educational materials for parents/carers and health professionals, restricted
prescription details and controlled access/product consent form, including
communication media, distribution modalities, and any other aspects of the
programme, with the National Competent Authority. </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Strimvelis will be administered at a specialist transplant centre,
and by physicians with previous experience in the treatment and management of
patients with ADA-SCID and the use of autologous CD34+ <i>ex vivo</i> gene
therapy products. A completed product consent form is required prior to
initiating treatment.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>The educational materials should address the following safety
concerns/key elements: Autoimmunity, Unsuccessful response to gene therapy, and
Malignancy due to insertional oncogenesis (e.g. leukaemia, myelodysplasia).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post-authorisation
measures</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>The MAH shall complete, within the stated timeframe, the below
measure:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
  lang=EN-GB>Description</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
  lang=EN-GB>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non-interventional
  PASS: In order to investigate the long term safety and efficacy of Strimvelis
  gene therapy, the MAH should conduct and submit the results of a long term
  prospective, non-interventional follow up study using data from a registry of
  patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID)
  treated with Strimvelis. The MAH will follow up on the risk of
  immunogenicity, insertional mutagenesis and oncogenesis as well as hepatic
  toxicity. The MAH will review the occurrence of angioedema, anaphylactic
  reactions, systemic allergic events and severe cutaneous adverse reactions
  during the FU period, particularly in those patients who had unsuccessful
  response and received ERT or SCT. The MAH will also evaluate
  intervention-free survival.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The MAH shall
  plan to include regular progress reports of the registry in the PSUR and
  provide interim study reports every 2 years until the registry finishes.
  Interim registry reports shall be submitted every 2 years.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The final
  clinical study report should be submitted after the 50<sup>th</sup> patient
  has 15 year follow-up visit; Q4 2037.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>OUTER CONTAINER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis 1-10 million cells/ml dispersion
for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An autologous CD34<sup>+</sup> enriched
cell fraction that contains CD34<sup>+</sup> cells transduced with retroviral
vector that encodes for the human ADA cDNA sequence with a concentration of
1-10&nbsp;million CD34<sup>+</sup> cells/ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Also contains sodium chloride.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Dispersion for
infusion</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>No. of infusion bags:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Total cell number:        x
10<sup>6</sup></span></p>

<p class=MsoNormal><span lang=EN-GB>CD34<sup>+</sup> cells/kg:            x 10<sup>6</sup></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For autologous use only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Exp.: {DD MMM YY} {hh:mm}</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store at 15-30</span><span lang=EN-GB
style='font-family:Symbol'>°</span><span lang=EN-GB>C</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>This medicine
contains genetically-modified cells. </span></p>

<p class=MsoNormal><span lang=EN-GB>Unused medicine must be disposed of in
compliance with the local biosafety guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Orchard Therapeutics (Netherlands) BV</span></p>

<p class=MsoNormal><span lang=EN-GB>Prins Bernhardplein 200, </span></p>

<p class=MsoNormal><span lang=EN-GB>1097 JB Amsterdam, </span></p>

<p class=MsoNormal><span lang=EN-GB>the Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/16/1097/001 </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER, DONATION AND PRODUCT CODES</span></b></p>

</div>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Lot:  </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Patient ID:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Not applicable.</span><span lang=EN-GB
style='color:green'> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:lightgrey'>Not applicable.</span><span
lang=EN-GB style='display:none'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>INFUSION
BAG</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis 1-10 million cells/ml dispersion
for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Exp.: {DD MMM YY} {hh:mm}</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER, DONATION AND PRODUCT CODES</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Lot:  </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Patient ID:</span></p>

<p class=MsoNormal><span lang=EN-GB>Bag No.:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Total cell number:        x
10<sup>6</sup></span></p>

<p class=MsoNormal><span lang=EN-GB>CD34<sup>+</sup> cells/kg:             x 10<sup>6</sup></span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For autologous use only.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient or carer</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Strimvelis 1-10 million cells/ml dispersion for infusion</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Autologous
CD34<sup>+</sup> enriched cell fraction that contains CD34<sup>+</sup> cells
transduced with retroviral vector that encodes for the human ADA cDNA sequence</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><img border=0 width=21 height=18 id="Picture 1"
src="Strimvelis_files/image002.png" alt="BT_1000x858px"><span lang=EN-GB>This
medicine is subject to additional monitoring. This will allow quick
identification of new safety information. You can help by reporting any side
effects you may get. See the end of section 4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal'><b><span lang=EN-GB>Read all of this leaflet carefully before you (or your
child) are given this medicine because it contains important information for
you.</span></b></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you (or your child) get any side effects,
talk to your doctor or nurse. This includes any possible side effects not
listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Your doctor will give you a Patient
Alert Card. Read it carefully and follow the instructions on it.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Always show the Patient
Alert Card to your doctor or nurse when you see them or if you go to hospital.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.    What Strimvelis is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.    What you need to know before you (or your child) are given Strimvelis</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.    How Strimvelis is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.    Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.    How to store Strimvelis</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.    Contents of the pack and further information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1.       What Strimvelis is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strimvelis is a type of medicine called a <b>gene therapy</b>. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strimvelis is used to treat a serious condition called <b>ADA-SCID</b>
(<i>Adenosine Deaminase-Severe Combined Immune Deficiency</i>). With this
condition the immune system does not work properly to defend the body against
infections. People with ADA-SCID cannot produce enough of an enzyme called <i>adenosine
deaminase (ADA)</i> because the gene to make it is faulty.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strimvelis is used to treat ADA-SCID when there is no suitable match
from a family member to donate stem cells from their bone marrow for a
transplant.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is made specially for each
patient, using the patient’s own bone marrow cells. It works by putting a new
gene into stem cells in the bone marrow so they can make ADA.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strimvelis is given by a drip <i>(infusion)</i> into a vein <i>(intravenously)</i>.
For more information on what happens before and during treatment, see section 3,
<i>How Strimvelis is given</i>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2.       What you need to know before you (or your child) are given Strimvelis</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Strimvelis is
not suitable for some people</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis  must
not be given if you (or to your child):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        are <b>allergic</b> to any of the ingredients
of this medicine (<i>listed in section 6</i>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        have or have had a type of <b>cancer</b>
called <i>leukaemia</i> or <i>myelodysplasia</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        have tested positive for <b>HIV or some other
infections</b> (your doctor will advise you about this)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        have already been treated with <b>gene
therapy</b></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor or nurse before you (or your child) are given this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis is
made specially from the patient’s own cells. It must never be given to anyone
else.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Inserting a new gene
into the DNA could cause leukaemia. In clinical trials of gene therapy for
other diseases (not ADA-SCID), some patients developed leukaemia or other cancers
of the blood system. This has not been seen in any patient treated with
Strimvelis; however, during long-term follow up your doctor has been advised to
monitor you (or your child) for any signs of leukaemia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After you (or
your child) have been treated with Strimvelis, you or your child will not be
able to donate blood, organs or tissues at any time in future. This is because
Strimvelis is a gene therapy </span><span lang=EN-GB>product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>When Strimvelis
treatment cannot be completed</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In some cases, it
might not be possible to go ahead with the planned treatment with Strimvelis.
There are several reasons why this might happen, for example:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>if there was a
     problem at the time the cells were taken for making the medicine</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>if there were
     not enough of the right type of cells to make the medicine</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>if the
     medicine got contaminated while it was being made</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN-GB>if there was a
     delay in the medicine reaching the clinic where treatment is being carried
     out.</span></li>
</ul>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In such cases, the doctor will give you (or your child) replacement stem
cells, using the backup sample that was collected and stored before treatment
started (<i>see also section 3, How Strimvelis is given</i>).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>You may need other
treatment</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis goes
through a range of tests before it is used.  Because it is given soon after it
is made, the final results of some of these tests will not be ready before the
medicine is given.  If the tests show anything that might affect you (or your
child), the doctor will treat you as appropriate.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant or breast-feeding, if you think you may be pregnant or are planning to
have a baby, tell your doctor before you are given this medicine. Strimvelis should
not be given to you if you are pregnant. If it is possible that you could become
pregnant, you must use a barrier contraceptive (such as condoms) during treatment
and for at least 6 months afterwards.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You should not
be given Strimvelis if you are breast-feeding.  It is not known whether the
ingredients of Strimvelis can pass into breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Strimvelis contains sodium</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains approximately </span><span lang=EN-GB
style='color:black'>3.5&nbsp;mg</span><span lang=EN-GB> </span><span
lang=EN-GB>sodium per millilitre. This should be taken into consideration by patients
on a controlled sodium diet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3.       How Strimvelis is given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strimvelis </span><span lang=EN-GB>is given by a drip <i>(infusion)</i>
into a vein <i>(intravenously)</i>. It </span><span lang=EN-GB>can only be
given in a specialised hospital, and by a doctor who is experienced in treating
patients with ADA-SCID and in using this type of medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strimvelis can
only be made if the doctor can collect enough of the right kind of cells from
the patient’s own bone marrow.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Before Strimvelis is made</span></b><span lang=EN-GB>, the doctor
will do tests to make sure that you (or your child) are not carrying certain
infections (see section 2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Two samples are collected</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will collect two samples of bone
marrow stem cells before the planned treatment:</span></p>

<p class=Bullet style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:8.0pt;font-family:"Arial",sans-serif'>•<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>the <b>backup sample</b>, at least 3 weeks before.  It will be
stored, to be given to the patient as replacement stem cells if Strimvelis cannot
be given or does not work <i>(see ‘When Strimvelis treatment cannot be completed’
 in section 2)</i></span></p>

<p class=Bullet style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:8.0pt;font-family:"Arial",sans-serif'>•<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>the <b>treatment sample</b>, 4 to 5 days before. It will be used to
make the Strimvelis, by putting a new gene into the cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Before and
during Strimvelis treatment</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>When</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>What is done</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Why</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>At least 3 weeks before</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>treatment</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Backup sample </span></b><span lang=EN-GB>of stem cells collected</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>to be stored as a backup <i>(see above)</i></span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>About 4 to 5 days before</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>treatment</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Treatment sample </span></b><span lang=EN-GB>of stem cells
  collected</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>to make Strimvelis <i>(see above)</i></span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>3 days and 2 days before</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>treatment</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>A medicine called <b>busulfan </b>is given four times a day for
  two days (total of 8 doses)</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>to make the bone marrow ready for Strimvelis</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>About 15 to 30 minutes</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>before </span></b><span lang=EN-GB>treatment</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>An <b>antihistamine </b>medicine may be given</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>to make it less likely that you will react to the infusion</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=219 valign=top style='width:164.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Strimvelis is given…</span></b></p>
  </td>
  <td width=438 colspan=2 valign=top style='width:328.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>by a drip<i> </i>into a vein.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>This will take about 20 minutes</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them. The ones marked * may be
related to busulfan.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:.25in;line-height:
normal'><span lang=EN-GB>These may affect <b>more than 1 in 10 people</b>:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>runny or blocked nose (<i>allergic rhinitis</i>)</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>wheezing, difficulty breathing (<i>asthma)</i></span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>inflamed itchy skin (<i>atopic dermatitis, eczema</i>)</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>raised temperature (<i>pyrexia</i>)</span></li>
</ul>

<p class=MsoListParagraph><span lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>underactive thyroid gland (<i>hypothyroidism</i>)</span></li>
</ul>

<p class=MsoListParagraph><span lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>high blood pressure (<i>hypertension</i>)*</span></li>
</ul>

<p class=MsoListParagraph><span lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>decreases in the number of red or white blood cells (<i>anaemia,
     neutropenia</i>)*</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>increases in liver enzymes*</span></li>
</ul>

<p class=MsoListParagraph><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>blood test results positive
for <i>antinuclear antibody</i></span><span lang=EN-GB> <i><span
style='color:black'>and smooth muscle antibody</span></i></span></p>

<p class=MsoListParagraph><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>If
you have any questions about symptoms or side effects, or if any symptoms
concern you</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB style='font-family:Symbol'>®</span></b><b><span lang=EN-GB>  Talk to
your doctor or nurse.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>C<b>ommon</b> <b>side effects</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>These may affect <b>up to 1 in 10 people</b>. They are all caused by
the immune system becoming over-active and attacking the body’s own tissues.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=tabletextNS style='margin-left:.5in;text-indent:-.25in'><span
lang=X-NONE style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>red
or purple dots on the skin, bleeding under the skin (<i>immune thrombocytopenic
purpura</i>)</span></p>

<p class=tabletextNS style='margin-left:.5in'><span lang=X-NONE
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=tabletextNS style='margin-left:.5in;text-indent:-.25in'><span
lang=X-NONE style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>inflamed
thyroid gland (<i>autoimmune thyroiditis</i>)</span></p>

<p class=tabletextNS><span lang=X-NONE style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>weakness and pain in the feet and hands (<i>Guillain-Barré syndrome</i>)</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB style='color:black'>inflamed liver (<i>autoimmune hepatitis</i>)</span></li>
</ul>

<p class=MsoListParagraph><span lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>reduced numbers of  blood cells (<i>autoimmune haemolytic
     anaemia, autoimmune aplastic anaemia</i>)</span></li>
</ul>

<p class=MsoListParagraph><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB style='color:black'>blood test results positive for <i>antineutrophil
     cytoplasmic antibody </i></span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any questions about symptoms or side effects, or if any
symptoms concern you</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB style='font-family:Symbol'>®</span></b><b><span lang=EN-GB>  Talk to
your doctor or nurse.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB style='font-family:TimesNewRoman'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you get any
side effects, talk to your doctor or nurse.<span style='color:red'> </span>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       How to store Strimvelis</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date and time (EXP) which
is stated on the container label and infusion bag label.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store at 15-30</span><span lang=EN-GB
style='font-family:Symbol'>°</span><span lang=EN-GB>C.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater. As this medicine
will be given by a qualified doctor, they are responsible for correct disposal
of the product. These measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Strimvelis contains </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is autologous (the
patient’s own) CD34<sup>+</sup> enriched cell fraction that contains CD34<sup>+</sup>
cells transduced with retroviral vector that encodes for the human ADA cDNA </span><span
lang=EN-GB>sequence</span><span lang=EN-GB>. The concentration is 1&#8209;10&nbsp;million
CD34<sup>+</sup> cells/ml.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredient is sodium chloride (<i>see
section 2, Strimvelis contains sodium</i>).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Strimvelis </span><span lang=EN-GB>looks like </span></b><b><span
lang=EN-GB>and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strimvelis is a cloudy to clear, colourless to pink dispersion of
cells for infusion, which is supplied in one or more infusion bags. The infusion
bags are provided in a closed container.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Orchard Therapeutics (Netherlands) BV</span></p>

<p class=MsoNormal><span lang=EN-GB>Prins Bernhardplein 200, </span></p>

<p class=MsoNormal><span lang=EN-GB>1097 JB Amsterdam, </span></p>

<p class=MsoNormal><span lang=EN-GB>the Netherlands</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>AGC Biologics S.p.A.<br>
58 Via Olgettina<br>
20132<br>
Milan<br>
ITALY</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in MM/YYYY.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>.</span><span lang=EN-GB> </span><span
lang=EN-GB>There are also links to other websites about rare diseases and
treatments. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This leaflet is
available in all EU/EEA languages on the European Medicines Agency website.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-----------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is transported directly to the
medical facility where the infusion will be administered. The infusion bag is
placed inside a closed outer container. The bags must be kept in the outer
container until ready to use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is intended solely for
autologous use. The identity of the patient must be matched with the essential
unique patient information on the infusion bag(s) and/or outer container prior
to infusion. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Gently agitate the
infusion bag to re-disperse any cellular aggregates, administer using a
transfusion administration set with filter to remove any remaining cellular
aggregates.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following administration, a saline filled 50&nbsp;ml
syringe should be used to flush the bag through.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains genetically-modified
cells. Local biosafety guidelines applicable should be followed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Strimvelis is not tested for transmissible
infectious agents. Healthcare professionals handling Strimvelis should
therefore take appropriate precautions to avoid potential transmission of
infectious diseases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Work surfaces and material which have
potentially been in contact with Strimvelis must be decontaminated with
appropriate disinfectant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local biosafety requirements.</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
